Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $582000.0.

  • Inhibrx Biosciences' Depreciation & Amortization (CF) fell 2342.11% to $582000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 3777.07%. This contributed to the annual value of $2.3 million for FY2024, which is 9185.56% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Depreciation & Amortization (CF) of $582000.0 as of Q3 2025, which was down 2342.11% from $662000.0 recorded in Q2 2025.
  • Inhibrx Biosciences' Depreciation & Amortization (CF)'s 5-year high stood at $760000.0 during Q3 2024, with a 5-year trough of $295000.0 in Q2 2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $510000.0, with a median of $528500.0 in 2024.
  • As far as peak fluctuations go, Inhibrx Biosciences' Depreciation & Amortization (CF) skyrocketed by 15000.0% in 2024, and later plummeted by 2342.11% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Depreciation & Amortization (CF) stood at $298000.0 in 2023, then surged by 131.21% to $689000.0 in 2024, then fell by 15.53% to $582000.0 in 2025.
  • Its last three reported values are $582000.0 in Q3 2025, $662000.0 for Q2 2025, and $675000.0 during Q1 2025.